S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:ACOR

Acorda Therapeutics Competitors

$5.82
-0.23 (-3.80 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.65
Now: $5.82
$6.07
50-Day Range
$4.10
MA: $6.74
$8.04
52-Week Range
$2.53
Now: $5.82
$9.84
Volume148,715 shs
Average Volume1.53 million shs
Market Capitalization$46.53 million
P/E Ratio1.05
Dividend YieldN/A
Beta0.75

Competitors

Acorda Therapeutics (NASDAQ:ACOR) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying ACOR stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Acorda Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Acorda Therapeutics (NASDAQ:ACOR) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

75.2% of Amgen shares are held by institutional investors. 6.8% of Acorda Therapeutics shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Acorda Therapeutics and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acorda Therapeutics29.71%-8.60%-3.51%
Amgen29.42%95.55%15.52%

Volatility & Risk

Acorda Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Acorda Therapeutics and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acorda Therapeutics02002.00
Amgen0111402.56

Acorda Therapeutics currently has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Amgen has a consensus target price of $256.0909, suggesting a potential upside of 13.86%. Given Acorda Therapeutics' higher possible upside, equities analysts clearly believe Acorda Therapeutics is more favorable than Amgen.

Earnings & Valuation

This table compares Acorda Therapeutics and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49
Amgen$23.36 billion5.56$7.84 billion$14.8215.18

Amgen has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Acorda Therapeutics on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Acorda Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Acorda Therapeutics29.71%-8.60%-3.51%

Volatility and Risk

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and Acorda Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1121202.44
Acorda Therapeutics02002.00

Gilead Sciences presently has a consensus target price of $96.0370, suggesting a potential upside of 56.41%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Gilead Sciences and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.43$5.39 billion$6.1410.00
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49

Gilead Sciences has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Acorda Therapeutics on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vertex Pharmaceuticals and Acorda Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Acorda Therapeutics29.71%-8.60%-3.51%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Acorda Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042312.89
Acorda Therapeutics02002.00

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, suggesting a potential upside of 37.31%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.27$1.18 billion$4.2949.55
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49

Vertex Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Acorda Therapeutics on 13 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Acorda Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Acorda Therapeutics29.71%-8.60%-3.51%

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Regeneron Pharmaceuticals and Acorda Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
Acorda Therapeutics02002.00

Regeneron Pharmaceuticals presently has a consensus target price of $625.8077, suggesting a potential upside of 38.89%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.14$2.12 billion$21.4720.99
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49

Regeneron Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Acorda Therapeutics on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Biogen and Acorda Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151202.22
Acorda Therapeutics02002.00

Biogen presently has a consensus target price of $304.4667, suggesting a potential upside of 11.58%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Biogen.

Volatility and Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Profitability

This table compares Biogen and Acorda Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Acorda Therapeutics29.71%-8.60%-3.51%

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Biogen and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.89$5.89 billion$33.578.13
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49

Biogen has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Acorda Therapeutics on 11 of the 14 factors compared between the two stocks.

Acorda Therapeutics (NASDAQ:ACOR) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Acorda Therapeutics and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acorda Therapeutics02002.00
Alexion Pharmaceuticals017712.36

Acorda Therapeutics presently has a consensus price target of $23.6667, suggesting a potential upside of 306.64%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 0.25%. Given Acorda Therapeutics' higher possible upside, equities analysts plainly believe Acorda Therapeutics is more favorable than Alexion Pharmaceuticals.

Risk & Volatility

Acorda Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Acorda Therapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acorda Therapeutics29.71%-8.60%-3.51%
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.8% of Acorda Therapeutics shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Acorda Therapeutics and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acorda Therapeutics$192.41 million0.24$-272,970,000.00($11.94)-0.49
Alexion Pharmaceuticals$4.99 billion6.73$2.40 billion$9.7415.68

Alexion Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Acorda Therapeutics on 12 of the 15 factors compared between the two stocks.


Acorda Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.92-1.2%$129.91 billion$23.36 billion18.14Gap Down
Gilead Sciences logo
GILD
Gilead Sciences
2.8$61.40-2.3%$76.97 billion$22.45 billion63.30Gap Down
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.55-0.2%$55.25 billion$4.16 billion26.84Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$450.57-0.6%$48.27 billion$7.86 billion16.47Analyst Report
News Coverage
Biogen logo
BIIB
Biogen
2.1$272.88-1.6%$41.57 billion$14.38 billion9.03
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$152.75-0.6%$33.58 billion$4.99 billion35.69Increase in Short Interest
Seagen logo
SGEN
Seagen
1.5$151.11-0.7%$27.38 billion$916.71 million59.49Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.6$136.12-3.5%$23.02 billion$876.29 million-61.59Analyst Downgrade
Insider Selling
News Coverage
Gap Up
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$148.10-1.0%$17.33 billion$219.75 million-18.91
Incyte logo
INCY
Incyte
1.9$78.66-0.3%$17.29 billion$2.16 billion-50.10Insider Buying
Novavax logo
NVAX
Novavax
1.2$231.23-4.2%$14.72 billion$18.66 million-44.30Upcoming Earnings
Gap Up
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.43-5.6%$14.06 billion$1.70 billion17.72Earnings Announcement
Insider Selling
High Trading Volume
News Coverage
Gap Down
Repligen logo
RGEN
Repligen
1.5$212.39-2.5%$11.18 billion$270.24 million259.01Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.51-2.5%$10.29 billion$788.10 million117.75Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$167.18-1.0%$7.43 billion$1.45 billion15.82Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$52.40-1.9%$7.33 billion$1.12 billion109.17Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
Exelixis logo
EXEL
Exelixis
1.9$21.66-1.4%$6.76 billion$967.78 million45.13Insider Selling
News Coverage
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$45.25-4.6%$6.12 billion$195.99 million282.81Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$96.00-1.2%$5.12 billion$1.11 billion30.87Analyst Upgrade
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.35-1.1%$4.85 billion$806.43 million-11.38Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$67.84-2.9%$4.70 billion$36.13 million-101.25Upcoming Earnings
Decrease in Short Interest
Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.28-2.9%$3.20 billion$182.24 million-10.68Upcoming Earnings
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$19.04-2.1%$3.03 billion$1.17 billion-41.39Gap Down
OPKO Health logo
OPK
OPKO Health
1.9$4.50-1.8%$3.02 billion$901.90 million-25.00Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.22-1.3%$2.38 billion$120.28 million-149.72Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$30.49-0.9%$2.29 billion$638.60 million-11.73Earnings Announcement
Analyst Report
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.78-2.9%$1.90 billion$48.83 million-14.18Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.19-1.5%$1.87 billionN/A-10.95Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.75-0.3%$1.70 billion$82.27 million-21.34
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.49-2.6%$1.63 billion$102.43 million-19.15Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.23-2.1%$1.48 billion$428.41 million13.38Analyst Report
News Coverage
MannKind logo
MNKD
MannKind
1.4$5.71-1.8%$1.33 billion$63.04 million-27.19Analyst Report
Analyst Revision
News Coverage
Gap Up
Codexis logo
CDXS
Codexis
1.1$22.11-3.9%$1.31 billion$68.46 million-63.17Earnings Announcement
Analyst Report
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.43-1.7%$1.16 billion$261.02 million5.83Analyst Downgrade
Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.33-12.8%$1.14 billion$150,000.00-7.61Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.08-1.6%$1.07 billion$3.57 million-12.14Analyst Report
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.65-3.8%$1.02 billion$227.19 million51.81Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.75-6.7%$964.01 million$35.22 million-6.39Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.19-4.0%$871.31 million$322.07 million-6.85News Coverage
Agenus logo
AGEN
Agenus
1.6$4.00-2.3%$760.60 million$150.05 million-3.67
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Curis logo
CRIS
Curis
1.1$9.84-0.9%$578.76 million$10 million-12.00Increase in Short Interest
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34Analyst Upgrade
Insider Buying
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43-5.0%$500.51 million$109.33 million-2.52News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.8$36.20-0.0%$399.00 million$18.37 million-32.61Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.8$2.35-0.4%$398.97 million$17.46 million-1.67Analyst Upgrade
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.72-0.3%$348.58 million$36.63 million-4.38Analyst Report
News Coverage
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.